**Lance LU**

(86) 139-5178-1452∣lancelu2018@qq.com∣Nanjing, China

**Personal Details**

Target English - Simplified Chinese Freelance Translator

Language pair English＞Simplified Chinese

Time Zone Beijing Time (GMT+8)

LinkedIn <https://www.linkedin.com/in/lance-lu-039088189/>

Skype live:pys-2307022018

**Education**

2003 –2007, Bachelor degree of English language and literature by Nanjing Normal University

**Professional Experience**

2009 –2013, In-House Translator, Jiangsu General Information Technology Co., Ltd.

* Translation, Proofreading and Quality Management for major clients

2014 – Now, Freelance Translator for **TransPerfect, RWS, United Language Group and Conversis**

* Translation
* MTPE
* Proofreading
* Quality Management

**Skills & Qualifications**

* Experienced English - Simplified Chinese translator, translating roughly over 10 million words in the past 13 years, and specializing in the translation of Medical and Life Science, IT, Market Research.
* Near-native understanding in English.
* Thorough knowledge of Medical and Life Science, Banking terminology, acquired through my experience in providing services for global language service providers including TransPerfect and RWS.
* Experience translating: Clinical Study Protocol, Investigator Brochure, Clinical Study Report, Informed Consent Form, Serious Adverse Events Form, Product Brochures, Presentations, Employee Handbooks, Technical Manuals, User Guides, IT, Apps, Policies and Procedures, Reports, Letters.
* Proficient in Microsoft Office-Word, Excel, PPT, and CAT tools such as Trados, MemoQ, Wordfast.
* Legacy Certification for Proofreading in English - Simplified Chinese from TransPerfect.

**Fields of Expertise**

* Life Science and Medical
* Market Research
* Convention & Exhibition
* Government
* General

**CAT Tool**

* Trados
* MemoQ
* Memsource
* Wordfast

**Services & Rates**

Translation 0.07 USD psw

MTPE 0.04 USD psw

Proofreading/editing 0.035 USD psw

Hourly rate 30 USD/hour

**Capacity**

Translation/MTPE 3,000 words/day

Proofreading/editing 10,000 words/day

**Project Experience (Non-Exhaustive List)**



**Life Science, Medical**

DSJ-2019-125509\_FU7\_Narrative Transaltion for 302 and 103 Study 19530

DUO-E protocol version 2.0 28Oct19\_formatted 62004

Ipsen Study 220 CSR Skeleton150120\_tc-EN 35804

ib-olaparib-edition-17\_CN\_Doc ID-004046617 v2.0 25250

ib-azd5363-edition-12- 43222

2.1.1 IB V13.0 21Aug2019\_EN\_Translated into CN\_17-Sep-2019 7772

d3615c00001-csp-v1 04Nov19 49684

Specialist Facing\_CTD\_Non-clinical 133734

WV41073\_IB\_RO7020531\_v5\_EN 38536

RO7049389 HBV Capsid Inhibitor\_IB\_ Version7\_EN\_May 2020 33700



**Life Science, Medical**

TASK174968\_EN-US-ZH-CN\_SRC\_AG120-C-009\_Site1561 10025

CVTTASK\_ARRAY-818-202 BRAFv600E Mutant NSCLC-Synopsis-Protocol V1 9583

C3291035\_PFIZ0074\_Lab Manual\_V1.0\_03SEP2019 13274

Vonoprazan-3002\_TKDA0143\_Lab Manual\_V1.0\_9DEC2019\_zh-CN 13114

Brigatinib-2002\_TKDA0138\_lab Manual\_ FINAL\_ V2.0\_12Nov2019 14744

SB12-3003\_SGBC0002\_lab manual\_V3.0\_11Nov2019 13728

E7090-J000-201-China ICF\_SCR2\_v2.1.0\_20191129\_EN\_clean 8715

TASK190682\_EN-US-ZH-CN\_CVTTASK\_Eli Lilly China policy\_20190830 15508

9161.2\_HRBM0003\_Lab Manual\_8Nov2019 8007

242604 Investigator\_Laboratory\_Manual\_1.0\_20191009\_zh-CN 7340



**Life Science, Medical**

IQVIAWO9\_AZA39875\_APD334-303\_Contract\_26Dec2018 26000

IQVIA WO8\_AZA39780\_APD334-302\_Contract\_26Dec2018FE 27158

Ansun DAS181-3-101 Change Order 1 (OXA65631)\_30July19clean 9779

Arena\_APD334-202\_CHina\_Main adult ICF\_V2.0CHN(en)01\_04Oct2019 11567

uniques-2019Y226JC 233AS101\_Main ICF 11832

BLU-667-1101\_2001-007\_NL-2019-000324\_FU02 Final CIOMS 5695

Garfield VTE Paper CRF Draft 3.9.1d 8285

Protocol Ozurdex Phase 4 China FINAL 8Aug2018 18459

Allergan\_1789-301-008\_Canfield User Manual\_07Nov2019 7105

CHN\_CRO Startup Service Agreement\_JNJ-CRO \_ Insourced\_Bilingual 7759



**Life Science, Medical**

242604 Investigator\_Laboratory\_Manual\_1.0\_20191009\_zh-CN 7340

YH25448-301\_Protocol\_Ver1\_18Oct2019.docx 41570

243873 CS1003-305 China Model ICF Main 20191126 2.0 English CL 10541

245026 Henlius Protocol Ver 2.0\_revised\_final to sponsor\_20190926 52817

2.7.4 summary-clin-safety 8756

EP0093\_IP\_Instructions\_for\_Handling\_v6.0(1) 15977

243483 Protocol Amendment 20191203 2.0 CHINA 30986

EP0092\_IM\_afternoon\_session\_Shanghai\_DRAFT\_17Oct2019 6922

246155 Astellas\_Site Questionnaire\_ENG\_final draft v0.3\_16Oct2019 4001



**Life Science, Medical**

04\_EU IM\_DDR genomic testing\_Foundation Medicine 11382

05\_C3441021\_Biomarker\_Slides\_June2019 11194

B7451014\_Study Level Model\_Assent ICF\_DRAFT PA5 MC - No 27421

C3441021\_CRF Completion Requirements \_V10\_PART 1\_20Sep2019 29146

CN-clean-Summary of Changes in a Revised Lorlatinib (PF-06463922) IB 8895

PF-06651600 IB February2019-chi 20981

B7451015-FWO-eResearch-ePRO\_Redacted 11098

03. C3291035 Protocol Training 28-Oct-2019- 8040

Pfizer Specialist Facing 32033

B7981015 Final Protocol Amendment 3 track changes 11232



**Life Science, Medical**

Informed Consent Form\_XX-Oct-2019\_Main\_4.0\_English\_Core\_MGL 14030

ib-lacosamide-dec-2019-addendum\_zh-CN 6107

TG-1000-01 Draft Protocol\_20200109 for Translation 11372

AP32788-15-101 Protocol Amend 5 2019-08-13 40211

SP0967 Yuwu Jiang HCP Consulting AGR 4747

0501-10US\_Pro\_v3.0\_09MAR20 (ID 145427) 23833



**Life Science, Medical**

V260-074 VRC Concomitant-use group draft for translation 7524

V260\_074-00 full protocol 30Oct2019 40173

MK3475-671 ProceduresManual\_V6\_FINAL 15237

RAPID Site Installation Guide\_CHARM\_v1\_25May18 10404



**Life Science, Medical**

Femibion Relaunch Training\_JL 4639

CHX\_IP014---Protocol Rev G\_Word Versio 29763

FWO-eResearch-ePRO\_Redacted 11598

2019Y226JC 233AS101\_Main ICF 11032

Specialist Facing\_CTD\_Non-clinical 133034



**Software, IT Marketing**

IBV Weaving data fabric into hybrid multicloud-en 12300

IBV Report\_ZHCN 11078

IA optimized for AI and hybrid cloud-zhCN 39751

AIOps\_ZHCN 7800

X-force report\_ZHCN 25630

Data Fabric - 解决方案 - 中国 \_ IBM 19210

Translation File CAM-cadenceguide-Instana Executive 7800

jobid250671\_en\_zhcn\_red\_prepped\_en-us\_zh-cn 6012



**Banking, Software and IT**

|  |  |  |
| --- | --- | --- |
| American Express Point-of-Purchase - Guidelines (2).doc | 11454 | |
| Contactless\_Guidelines\_Oct2018 (2).doc | 1657 | |
| AEIPS Card Technical Specification v4.4.2.doc | 38201 | |
| JV Network Specifications Final as of 9-12-2017.docx | 3406 | |
| 2017 08 07 - Feasibility Study - Chapter 2.docx | 4302 | |
| 20170719\_Network License Application\_Risk and Compliance | | 19869 |
| \_V1.0\_Risk | |  |
| PIC-2017 08 07 - Feasibility Report - CH 4 Summary of System | | 13591 |
| Risk Compliance.docx | |  |
| Expresspay Terminal Technical Specification 4.0.1 | | 29451 |
| 1PIC-2017 08 07 - Feasibility Study - Summary Chapter 1.docx | | 5177 |
| batch 8 20170806\_Network License Application\_Risk | | 2549 |
| and Compliance\_Compliance\_Cardholder and Merchant Protection | |  |
| MCL.docx | |  |



**Banking, Software and IT**

|  |  |
| --- | --- |
| JSecure CA Interface Guide\_V2.4\_eng.docx | 6040 |
| JSecure Issuer Implementation Guide Ver1.4.docx | 8957 |
| (ENG)Operations Manual | 7289 |
| (ENG)Regulations | 17057 |
| JCB CA Interface Guide | 6276 |
| JSecure Acquirer Implementation Guide Ver.1.4.docx | 7274 |



**Economic, Market Research and Government**

Book Draft 23 April 2018 for translation to Chinese.docx 29129

PRC-SBD-GOODS-14-12-2018-clean.docx 28565

PPPCEF\_DraftBusiness Case\_30Jul16.docx 29603

26 07 2018 FCP GP 4th Version-.docx 25350

Final report - 15 August 2016 -.docx 38718

PRCPPP\_ProPrivate\_26Aug16\_ENG\_v1-.docx 8376

Promoting Inland Waterway Transport FA\_PRINT.pdf 31001

strategy-2030-main-document.docx 37110

**Publications (Non-Exhaustive List)**

(<https://www.adb.org/zh/news/asia-and-pacific-growth-steady-amid-global-trade-tensions-adb>)

(<https://www.adb.org/zh/news/adb-open-new-singapore-office-expand-private-sector-operations>)



**Economic, Market Research and Government**

Economic\_Impact\_of\_Road\_Traffic\_Injuries\_Final\_EN.docx 34109

World Bank V4.docx 12806

ChallengesOpportunities\_ChinaWaterQualityMarkets\_063017.docx 8524

CleanCopyeditedFINAL Individual City Reports dra.docx 21993

China NDGs Overview Review Draft.docx 69623

160707-00102-Hotel User Guide-Version 2 0.docx 75355

1708458\_Climate\_Smart\_Mining\_Web 39402

2019001880CHNeng001.docx 41360



**Convention & Exhibition, Marketing**

Proposal for Chinese participation to CeBIT 2018.pptx\_zho-CN.rtf 6011

4-art\_schaefer\_rahmenveranstaltungen\_eng\_2017-02-13-20.doc 4315

7-prae\_schaefer\_china\_eng\_2017-02-13-20.pptx\_zho-CN.rtf 2056

Imagebrochure\_Deutsch Messe -EN.docx 9908

3-art\_schaefer\_emowirtschaft\_china\_2017-02-13\_eng.docx 1550

3-art\_schaefer\_emowirtschaft\_china\_2017-02-13\_eng.doc\_zho-CN.rtf 1972



**Government**

ToT Course FG with cover.doc 26088

Proposal of Blood center(Lao).docx 8258

E IP 14 Constitutional amendments.docx 7016

8-E AI 2.3 Update to Plan and Budget 2016-2020.docx 12094

10-E AI 5 Development of Strategy 2030.docx 7229

48840210\_CPRO\_Handbook.pdf 9714

1.Strengthening IHL protecting persons deprived of their lib.docx 22892

5. the safety and security of humanitarian volunteers.docx 3499